Moreover, in ovarian cancer cells, CLDN4 was found to interact with both α- and β-tubulins, thereby affecting the structure and dynamic state of the microtubules and reducing apoptotic responses to microtubule-targeting agents (MTAs), including paclitaxel [35]. This evidence concerns the gene CLDN4 and ovarian carcinoma.